NEW YORK (GenomeWeb News) – BioChain has licensed Epigenomics' methylated Septin9 biomarker for the detection of colorectal cancer and will start offering an assay based on the marker in China, Epigenomics announced today.

BioChain will offer the assay through its Beijing-based independent reference laboratory — equivalent to a CLIA lab — called Beijing BioChain Medical Laboratory. BioChain manufactures life science tools and molecular genetics diagnostics and has offices in Newark, Calif., and Beijing.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.